March 28th 2023
Dostarlimab plus chemotherapy appears to improve progression-free survival vs placebo plus chemotherapy in patients with recurrent endometrial cancer in the phase 3 RUBY trial.
Questionnaires Are Comparable in Assessing Lymphedema in Endometrial CancerMarch 27th 2023
The lower extremity lymphedema screening questionnaire and gynecological cancer lymphedema questionnaire appear to demonstrate comparable utility in assessing lymphedema in patients with advanced endometrial cancer.
Racial Disparities in Mortality from Type II Endometrial Cancer Underscores Need for Research On ‘Disproportionate Disease Burden’December 16th 2022
Non-Hispanic Black patients appeared to have higher disease-specific mortality rates than patients of other races, with clinicopathologic factors playing the greatest role in the disparity.
Dostarlimab/Chemotherapy Combo Elicits Significant Survival Benefit in Advanced/Recurrent Endometrial CancerDecember 6th 2022
Treatment with dostarlimab plus chemotherapy demonstrated a statistically significant improvement in progression-free survival compared with placebo and chemotherapy among patients with advanced or recurrent endometrial cancer.
Letrozole/Abemaciclib Demonstrate Promising, Long-Lasting Activity in Recurrent ER+ Endocrine CancerNovember 14th 2022
In patients with estrogen receptor–positive recurrent endometrial cancer, letrozole and abemaciclib combination therapy produced an objective response rate of 30% and a median progression-free survival of 9.1 months.
Updated Recommendations from ASTRO for the Adjuvant Treatment of Endometrial CancerNovember 9th 2022
In a new set of guidelines by the American Society for Radiation Oncology for the treatment of adjuvant endometrial cancer, experts noted that molecular characterization data should be considered when making recommendations.
VBT Yields Less Urethra Radiation Exposure in Endometrial Cancer vs EBRT in CRCOctober 12th 2022
Results from a retrospective cohort study indicated that vaginal brachytherapy yielded less radiation exposure to the female urethra in patients with endometrial cancer than external beam radiation therapy for those with colorectal cancer.
Pembrolizumab Yields Lasting Anti-Tumor Activity in MSI-H, dMMR Advanced Endometrial CancerSeptember 19th 2022
Long-term follow-up from the phase 2 KEYNOTE-158 trial showed enduring anti-tumor activity when pembrolizumab was used to treat patients with microsatellite instability–high/mismatch repair deficient advanced endometrial cancer.
Updated Findings Continue to Support Lenvatinib/Pembrolizumab Combination in Advanced Endometrial CancerSeptember 11th 2022
Findings from an updated safety and efficacy analysis of the phase 3 KEYNOTE-775 trial were consistent with the primary analysis and highlighted notable improvements in outcomes among patients with advanced endometrial cancer treated with lenvatinib and pembrolizumab vs physician’s choice.
ddPCR Analysis Effective in Identifying POLE Mutations in Endometrial Cancer, Study FindsJuly 22nd 2022
Investigators recommended that ddPCR testing and immunohistochemical staining be used to detect POLE status and p53/mismatch repair status, respectively, and allow for more rapid classification and risk-stratification.
Investigators Identify 12 Immune-Related lncRNAs That Could Impact Endometrial Cancer PrognosisJuly 14th 2022
Several immune-related long noncoding RNA signatures—including PCAT19 and SCARNA9—may be associated with prognosis in patients with endometrial cancer, according to the new research.
Body Mass Index May be Predictive of Sentinel Lymph Node Mapping Failure in Apparent Early-Stage Endometrial CancerJune 2nd 2022
High body mass index in patients with apparent early-stage endometrial cancer may be predictive of sentinel lymph node mapping failure and decrease overall detection rate.
Early Findings Indicate Vistusertib Plus Anastrozole Improved Survival in HR+ Advanced Endometrial CancerMay 25th 2022
Findings from the phase 1/2 VICTORIA trial showed the combination of vistusertib plus anastrozole improved response and survival for patients with hormone receptor–positive recurrent or metastatic endometrial cancer vs anastrozole alone.
Durvalumab Plus Olaparib Is Well Tolerated But Misses Trial End Point of PFS in Advanced Endometrial CancerMay 17th 2022
Findings from the phase 2 DOMEC trial showed that although durvalumab plus olaparib was well tolerated, it missed the study’s primary end point of progression-free survival in patients with metastatic or recurrent endometrial cancer.